Novo Nordisk’s Wegovy In Medicare Part D: Coverage May Not Be The Only Problem

Prospect of facing price negotiation in Part D may lead Novo Nordisk to consider earlier-than-currently-planned generic competition for its older semaglutide drug for diabetes, Ozempic.